ONWARDS and upwards for basal insulin
-
Published:2023-06
Issue:10392
Volume:401
Page:1904-1905
-
ISSN:0140-6736
-
Container-title:The Lancet
-
language:en
-
Short-container-title:The Lancet
Reference12 articles.
1. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial;Mathieu;Lancet,2023
2. New insulin glargine 300 Units·mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units·mL-1;Becker;Diabetes Care,2015
3. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine;Heise;Expert Opin Drug Metab Toxicol,2015
4. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials;Ratner;Diabetes Obes Metab,2013
5. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension;Riddle;Diabetes Obes Metab,2015